Incretin-based therapies: where will we be 50 years from now?

  title={Incretin-based therapies: where will we be 50 years from now?},
  author={Juris J Meier and Michael A Nauck},
The development of incretin-based therapies (glucagon-like peptide 1 [GLP-1] receptor agonists and dipeptidyl peptidase-4 [DPP-4] inhibitors) has changed the landscape of type 2 diabetes management over the past decade. Current developments include longer-acting GLP-1 receptor agonists, fixed-ratio combinations of GLP-1 analogues and basal insulin, as well as implantable osmotic minipumps for long-term delivery of GLP-1 receptor agonists. In longer terms, oral or inhaled GLP-1 analogues may… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 15 times over the past 90 days. VIEW TWEETS
8 Citations
22 References
Similar Papers


Publications citing this paper.
Showing 1-8 of 8 extracted citations


Publications referenced by this paper.
Showing 1-10 of 22 references

Similar Papers

Loading similar papers…